Condition: NSCLC · Sponsor: Tang-Du Hospital
This is a single-arm, phase 2 study to investigate the efficacy and safety of sunvozertinib as neoadjuvant and adjuvant treatment for stage II-IIIB non-small-cell lung cancer patients with EGFR exon20 insertion mutation.
This description comes directly from the study's public registry record.
Xiaolong Yan · +86 15991269383 · yanxiaolong@fmmu.edu.cn
Always discuss trial participation with your own doctor first.
| Second Xiangya Hospital of Central South University | Changsha, Hunan, China | Not Yet Recruiting |
| General Hospital of Ningxia Medical University | Yinchuan, Ningxia, China | Not Yet Recruiting |
| Tangdu Hospital | Xi'an, Shaanxi, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06864624